NCT05748873View on ClinicalTrials.gov

Promising ROd-cone DYstrophy Gene therapY

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

April 12, 2023

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2030

Conditions
Retinitis Pigmentosa
Interventions
DRUG

SPVN06

AAV-RdCVF-RdCVFL

Trial Locations (6)

15213

RECRUITING

UPMC Eye Center, Pittsburgh

33136

RECRUITING

Bascom Palmer Eye Institute/University of Miami, Miami

75012

RECRUITING

CHNO XV-XX Paris - CIC 1423, Paris

75231

RECRUITING

Retina Foundation of the Southwest, Dallas

97239

RECRUITING

Casey Eye Institute, Portland

02114

RECRUITING

Mass Eye and Ear, Boston

Sponsors

Lead Sponsor

SparingVision
All Listed Sponsors
lead

SparingVision

INDUSTRY

NCT05748873 - Promising ROd-cone DYstrophy Gene therapY | Biotech Hunter | Biotech Hunter